key: cord-0777675-fz08k0vf
authors: Satué-Gracia, Eva M; Vila-Córcoles, Angel; de Diego-Cabanes, Cinta; Vila-Rovira, Angel; Torrente-Fraga, Cristina; Gómez-Bertomeu, Frederic; Hospital-Guardiola, Imma; Ochoa-Gondar, Olga; Martín-Luján, Francisco
title: “Susceptibilidad y riesgo de infección por SARS-COV-2 en adultos mayores de 50 años en el área de Tarragona”
date: 2021-05-07
journal: Med Clin (Barc)
DOI: 10.1016/j.medcli.2021.03.027
sha: 11f6a755ff4d3da328207eb97366e8855ff1e838
doc_id: 777675
cord_uid: fz08k0vf

Objective: To analyse susceptibility/ risk of suffering COVID19 among adults with distinct underlying medical conditions. Methods: Population-based cohort study involving 79,083 individuals ≥50 years old in Tarragona (Southern Catalonia, Spain). Baseline cohort characteristics (demographic, pre-existing comorbidities, chronic medications and vaccinations history) were established at study start (01/03/2020) and primary outcome was laboratory-confirmed COVID19 occurred among cohort members throughout 01/03/2020-30/06/2020. Risk of suffering COVID19 was evaluated by Cox regression, estimating multivariable hazard ratios (HRs) adjusted for age/sex and pre-existing comorbidities. Results: Across study period, 536 laboratory-confirmed COVID19 cases were observed (mean incidence: 39.5 cases per 100,000 persons-week). In multivariable-analysis, increasing age/years (HR: 1.01; 95% CI: 1.00-1.02), nursing-home (HR: 20.19; 95% CI: 15.98-25.51), neurological disease (HR: 1.35; 95% CI: 1.03-1.77), taking diuretics (HR: 1.39; 95% CI: 1.10-1.75), antiplatelet (HR: 1.36; 95% CI: 1.05-1.76) and benzodiazepines (HR: 1.24; 95% CI: 1.00-1.53) increased risk; conversely, taking angiotensin-converting-enzyme inhibitors (HR: 0.78; 95% CI: 0.61-1.00), angiotensin-receptor-blockers (HR: 0.70; 95%CI: 0.51-0.96) and statins (HR: 0.75; 95% CI: 0.58-0.96) were associated with reduced risk. Among community-dwelling individuals, pre-existing cancer, renal and cardiac disease appeared also related with an increased risk, whereas influenza vaccination was associated with reduced risk. Conclusion: In a setting with relatively low incidence of COVID19 across the first wave of pandemic period, increasing age, nursing-home residence and multiple comorbidities appear predisposing for COVID19 among middle-aged/older adults. Conversely, statins, angiotensin-receptor blockers/inhibitors and influenza vaccination were related with decreased risk.

J o u r n a l P r e -p r o o f

Objetivo: Analizar incidencia y riesgo/susceptibilidad de sufrir COVID19 en adultos según distintas condiciones médicas preexistentes.

Métodos: Cohorte de base poblacional que incluyó 79.083 personas ≥50 años en Tarragona.

Características basales de la cohorte (edad/sexo, comorbilidades, medicaciones crónicas) se establecieron a 01/03/2020 y se registraron todos los casos de COVID19-confirmada ocurridos en miembros de la cohorte hasta 30/06/2020. Para estimación de riesgos se realizó regresión de Cox, con cálculo de Hazard ratios (HRs) ajustados por edad, sexo y comorbilidad. 1.24; IC 95%: 1.00-1.53) se asociaron con un riesgo aumentado de COVID-19 analizando la totalidad de la cohorte; contrariamente, medicación IECA (HR: 0.78; IC 95%: 0.61-1.00), ARA-II (HR: 0.70; IC 95%: 0.51-0.96) y estatinas (HR: 0.75; IC 95%: 0.58-0.96) se asociaron con menor riesgo. Entre personas no institucionalizadas, cáncer, nefropatía y cardiopatía se asociaron con mayor riesgo y vacunación antigripal con menor riesgo.

Conclusión: En un área con relativamente baja incidencia de COVID19, edad, institucionalización y múltiples comorbilidades aumentaron el riesgo/susceptibilidad de sufrir COVID19. Contrariamente, estatinas, inhibidores del sistema renina-angiotensina y vacunación antigripal se asociaron con menor riesgo.

Coronavirus; SARS-COV-2; COVID19; Incidencia; Riesgo.

The novel severe acute respiratory syndrome coronavirus 2 (SARS-COV-2), discovered in December 2019 following an outbreak of pneumonias in Wuhan, China, causes an infectious illness known as coronavirus disease 2019 (COVID19). The World Health Organisation (WHO), due to the alarming levels of spread of the disease and its severity, declared it to be a pandemic on March 11, 2020. 1 Currently the disease continues to spread in the world, with almost 100 million confirmed cases in later January 2021. 2 In Spain there was a first wave in March-April that was considered contained on May 11, with a total of just over 250,000 diagnosed cases; the contagion curve grew again in June until reaching the maximum peak of second wave in mid-October and as of later January 2021, in the middle of the third wave, the Spanish Ministry of Health reports 2,705,001 cases and almost 58,000 deaths. 3 There is much information updating COVID-19 surveillance epidemiological data (number of cases and deaths by demographic characteristics, accumulated incidences, ratios for positive laboratory testing, etc) but there is few population-based data on specific incidence and susceptibility for SARS-COV-2 infection in different population subgroups with distinct underlying -believed as at-risk-conditions. 2, 3 Earlier studies regarding clinical characteristics and prevalence of comorbidities among COVID19 patients reported that cardiovascular disease (including hypertension), chronic respiratory disease, renal disease, cancer, diabetes mellitus, obesity and smoking were major risk factors for severe COVID19. However, most of these results (mainly based on hospitalised severe cases) are likely confounded by age and other unadjusted variables (including other sociodemographic, medical or health care-related factors). [4] [5] [6] [7] Of note, COVID19 patients managed as outpatients were generally poorly represented in COVID19 research studies. [4] [5] [6] [7] In this sense, a UK report based on a primary care cohort found that positive SARS-CoV-2 testing was associated with similar risk factors (except smoking) as described for severe COVID19 in hospital settings. 8 Nevertheless, there is uncertainty about the possibility that some of these conditions although they increase the risk of severe COVID19, may not "per se" increase the risk of SARS-COV-2 infection. 9 In this context, we designed a large population-based cohort study aimed to investigate the incidence, clinical characteristics, susceptibility and risk profile of suffering COVID19 among middle-aged and older adults (who supported the greatest burden of COVID19 at this time) in the region of Tarragona across pandemic period. First-time analyses reporting earlier data have been published. 10, 11 The present report updates population-based incidence data and risk of suffering laboratory-confirmed COVID19 among cohort members by distinct underlying medical conditions (previous comorbidities, vaccinations' history and common chronic medications' use), reporting final data observed at the end of the planned study period (from 1st March to 30th June 2020).

The design, setting and study population have been extensively described elsewhere. 10, 11 Briefly, this is a population-based cohort study (began in April 2020) that included 79,083 persons ≥50 years-old in Tarragona area, whose total population (all-age) is 210,672 inhabitants. 12 The cohort incorporates all persons ≥50 years old assigned to 12 Primary Care Centres (PCCs) managed by the Institut Català de la Salut (ICS) in the study area (Tarragonés, Alt Camp and Conca de Barberà counties). The reference Hospital and Laboratory for the 12 participating PCCs were Hospital Universitari Joan XXIII and its Microbiological Department in the city of Tarragona. According to census data, the study cohort represents approximately 75% of inhabitants aged 50 years or older in the study area. 12 Cohort members were followed since March 1 st 2020 (date before the onset of the epidemic in the region), until the appearance of any study event (COVID19 diagnosis or death), or until the end of 4-month follow-up (June 30, 2020). The study was approved by the Ethics Committee Spanish legislation on biomedical studies, data protection and respect for human rights. 13 Considering public health surveillance emergency, informed consent for all cohort members was waived.

An institutional clinical research database earlier used for other cohort studies in the area (CAPAMIS), 14 was updated and became the primary data source for this COVID19 epidemiologic report; it includes administrative and clinical data (coded according to the International Classification of Diseases 10th Revision, ICD-10), extracted from the PCCs' clinical records electronic system, that operates since the 2000s. We collected sociodemographic characteristics, previous comorbidities, chronic medications and vaccinations' history for cohort members in order to establish their baseline conditions (at March 1, 2020).

When the COVID19 epidemic period onset in the area, two electronic alerts, linked to COVID19 laboratory tests results and ICD-10 codes for disease suspicion (B34.2 and B97.29), were added to the electronic clinical records system of PCCs. Subsequently, both data sources were associated in the anonymised research database used for this report. Vital status for all cohort members was considered according to administrative data periodically updated in the electronic PCCs' clinical records (Figure 1 shows Study scheme).

The main outcome was laboratory-confirmed COVID19 diagnosed by Reverse Transcription-Polymerase Chain Reaction (RT-PCR) or serological testing. For laboratory diagnosis of COVID19, guidelines of the Health Department of the Generalitat de Catalunya were implemented. 15 Of note, the availability of PCR testing was scarce during the first weeks of epidemic period, and they were prioritised for severe cases (requiring hospital admission) and

nursing-home residences (where several outbreaks took place), while less PCR tests were made among possible cases with mild symptoms managed as outpatient. For descriptive results we report suspected/presumptive COVID19 cases (persons coded as clinical suspicion alone without PCR tested) and, additionally, COVID19-excluded cases (PCR performed with a negative result) among cohort members across study period.

Besides socio-demographic (age, sex and type of residence as community-dwelling/nursing- In addition, baseline use of some common chronic medications, which could be hypothetically related with physiopathological mechanism of SARS-COV-2 infection or virulence (e.g., antihypertensive, antiplatelet/anticoagulant and/or anti-inflammatory drugs), were also considered as exposure covariables possibly related with the occurrence of COVID19 for the present study. Thus, active medication treatments in each cohort member on 01/03/2020, coded according to the Anatomical, Therapeutic, and Chemical classification system (ATC) of the World Health Organization, 16 were identified from the patient treatment plan registered in the PCC's clinical records system, and included the following therapeutic groups: antihypertensive (diuretics, beta-blockers, angiotensin-converting enzyme inhibitors [ACEIs], angiotensin II receptor blockers [ARBs], calcium channel blockers), statins, anticoagulants (warfarin and new oral anticoagulant drugs), antiplatelet drugs, antidiabetic drugs (insulin, oral antidiabetic drugs), inhaled respiratory drugs, antineoplastic agents, systemic corticosteroids, non-steroidal anti-inflammatory drugs (NSADs), chloroquine/hydroxychloroquine, antihistamines, proton-pump inhibitors and benzodiazepines. 16 Criteria used to define and collect pre-existing conditions and chronic medications use are extensively described in an appendix elsewhere. 1 A comorbidity/medication was considered absent if it was not recorded.

Descriptive statistics included frequencies, percentages, means and standard deviations (SD). Table 1) . 

Population-based clinical data on susceptibility and risk of SARS-COV-2 infection is limited. 9, 18 This large cohort study was aimed to assess population-based incidence of laboratoryconfirmed COVID19 among middle-aged and older adults with distinct underlying medical conditions in a well characterised geographic area (Tarragona region) during the first wave of the COVID19 epidemic (March-June 2020), investigating possible relationships between preexisting medical conditions with the susceptibility/risk of suffering COVID19.

As main result, we found a mean IR of 39.5 laboratory-confirmed COVID19 cases per 100,000

persons-week throughout study period, which is a relatively low incidence as compared to other Spanish or European regions during the same time period. 19, 20 .

During the study period (17.4 weeks since 1st March until 30th June 2020), approximately 5%

of cohort members were PCR tested (with 12.4% positive results). Taking this data into account, and considering that PCR test were scarcely available in the study area for patients with less severe symptoms during the first weeks of the epidemic period, the true incidence of COVID19 was logically underestimated. Nevertheless, considering the relatively low number of presumptive cases (clinical suspicion alone without PCR performed), our data also suggests that the overall number of infected people could be considerably lower than initially speculated (as showed by the national seroprevalence study). 21 Assuming this relatively little incidence, we found that increasing age, nursing-home residence, some pre-existing comorbidities (cancer, neurological, renal or cardiac disease and taking certain chronic medications (diuretics, antiplatelet drugs and benzodiazepines) were independent factors related to increased risk of suffering COVID19. In contrast, cohort members receiving statins or ACEIs/ARBs (and, in the case of community-dwelling individuals, those vaccinated against influenza in prior autumn) presented, after multivariable-adjustment, a decreased risk.

Of note, in the crude analyses several covariates (comorbidities, medications and vaccinations) appeared significantly associated with increased risk/susceptibility of suffering COVID19.

However, for most of them the significance disappeared after age&sex-adjustment and only a few remained independently associated with an increased risk after multivariable adjustments.

This highlights the importance of reporting adjusted data and note that differences in adjustment methods may explain, in part, the heterogeneous results reported to date evaluating the possible association between some pre-existing conditions and risk of COVID19. 22 At present, there is not clear evidence about possible clinical predisposing and protecting factors front SARS-COV-2 infection, and uncertainty surrounds this issue. 23 

If we consider demographic characteristics, apart from nursing-home residence that increased twenty-times the adjusted-risk of suffering laboratory-confirmed COVID19, we found that age increased approximately 1-2% for each year the adjusted-risk of suffering COVID19. While COVID19 was more frequent in women, sex did not alter the risk of infection in multivariable analysis.

Considering pre-existing comorbidities, only neurological disease (basically patients with a history of dementia and/or stroke living in nursing-home residences) was associated with increased multivariable-adjusted risk of infection in the analysis of full cohort. Concomitantly, previous cancer, renal disease and cardiac disease emerged associated with increased risk in subgroup analysis restricted to community-dwelling individuals.

In the present study, chronic respiratory disease, diabetes, hypertension and obesity did not emerge independently associated with significant increased risk of suffering laboratoryconfirmed COVID19 after multivariable-adjusted analyses. There is general accordance considering these conditions as major risk factors for poor prognosis in hospitalised COVID19

patients, but there is few data assessing their role in predisposing for SARS-COV-2 infection. 24 Surprisingly, smokers presented the lowest specific incidence rate of COVID19 in the present report, and smoking was associated with a reduced risk of COVID19, both in multivariable analyses evaluating the total study cohort and in the restricted to community-dwelling individuals. This unexpected result could be due to possible selection bias (e.g., those who are current smokers may be healthier whereas those who suffered tobacco consequences may be currently non-smokers). Notably, active smoking has been linked with decreased odds of a positive result SARS-COV-2 test in other studies. 8 Opposite findings about poor prognosis among smokers with COVID19 have been reported. 25, 26 Considering chronic medication use, receiving diuretics, antiplatelet drugs and benzodiazepines appeared associated with increased risk of suffering COVID19. In contrast, taking statins and ACEIs or ARBs emerged associated with decreased risk. At onset of COVID19 pandemic, after discovering that the host receptor for SARS-CoV-2 cell entry was the angiotensin-converting enzyme 2 (ACE2), it was feared that receiving ACEIs/ARBs could facilitate SARS-COV-2 infection and predispose to suffer severe COVID19. However, most recent studies have concluded that there is no clinical or experimental evidence supporting that ACEIs or ARBs augment the susceptibility to/severity of COVID19 at present. 7 Indeed, ACEIs/ARBs have been associated with lower incidence and/or improved outcomes in patients with lower respiratory tract infections, and with lower risk of all-cause mortality in COVID19 hospitalised patients. 27 Considering statins, while first studies reported opposite results, our data showing a decreased risk of laboratory-confirmed COVID19 among people taking statins is in accordance with conclusions of a recent meta-analysis on this concern. 28 Anyway, caution is recommended until further evidence emerges surrounding statin use in COVID19 patients.

Regarding other chronic medications that appeared associated with increased risk in the current study (i.e., diuretics, antiplatelet drugs and benzodiazepines), we have not a clear interpretation for this data. It is possibly due to an unresolved residual confounding, linked to unmeasured health-care-related factors or insufficient age-adjustment, but we also note that some of them (e.g., benzodiazepines) have already been reported associated with greater risk of pneumonia (common clinical manifestation in COVID19 patients).

Antihistamines' use was not associated with any statistically significant change in the risk of suffering COVID19 in the present study. We note that antihistamines' use was associated (marginally significative) with a lower risk of COVID19 in an earlier report, 11 but we also remark that it could be due to an alpha error considering that this final report has greater statistical power (since include more persons-time follow-up and greater number of events analysed).

Similar to data observed in earlier analyses, we found that influenza vaccination in prior autumn was associated with a reduction risk of suffering COVID19 among community-dwelling individuals. 10 Conversely, it was associated with a greater risk in the subgroup of nursing-home residents (where a protective association appeared for those who had received tetanus vaccination). While these associations could be due to residual confounding related with unmeasured life-style or healthcare factors, further investigations are needed exploring a possible immunity-related mechanism explanation. 29, 30 Major strengths in this study were the large size and representativity of the study cohort, that included almost 80,000 people and represented about 75% of the entire population over 50 years in the area, 12 and the use of survival analysis methods to precisely asses susceptibility and risk of suffering a SARS-COV-2 infection adjusting by important potential confounders (as socio-demographic, and medical underlying conditions clinically relevant).

Major limitations were related to its partially retrospective design and poor access to PCR tests at the beginning of the epidemic period in our setting, especially considering that the most specific diagnosis for COVID19 is a positive PCR test. Moreover, its reliability depends on the correct collection of nasopharyngeal swabs, moment of collection, sensitivity of tests and guidelines for testing followed throughout the study period. Due to above mentioned scarce availability of PCR tests they were mainly performed in hospitalised/severe patients and in nursing homes (after some outbreaks were detected). Thereby, patients with mild symptoms (many of them without PCR done) have been logically underestimated in this study.

Despite the large size of the cohort, there were relatively few events (536 laboratory-confirmed COVID19 cases), which limits statistical power. This is especially relevant in the subgroup of nursing-home residents where, even if great incidence occurred, only 191 confirmed COVID19 cases were collected and this fact largely affects the precision of estimates (confidence intervals very wide). Notwithstanding all mentioned limitations, authors emphasise the added value that provide adjustments (age&sex and multivariable), not present in many other studies.

Their importance is clearly evident if we compare, for example in Table 2 , crude with adjusted results. Nevertheless, caution is needed before multivariable HRs interpretation. Obviously, the multivariable models may be incorrect and incomplete. Multivariable analyses have inherent limitations and a residual confounding in estimated coefficients (due to unobserved, unmeasured or unknown factors) may not be excluded.

We must consider that the study was conducted in a single geographic area; thus, specific incidence data cannot be directly extrapolated to other regions with distinct epidemic conditions.

Nevertheless, we also note that the adjusted-risks estimated here may be helpful to better characterise the risk profile (socio-demographic, pre-existing conditions/comorbidities, chronic medication use) for suffering COVID19 among middle-aged and older adults living in a setting with low/moderate intensity of COVID19, as in the present study.

In summary, in this large population-based study that followed a cohort of 79,083 individuals ≥50 years old between March-June 2020 in Tarragona area, the incidence of laboratoryconfirmed SARS-COV-2 infection was relatively low (39.5 cases per 100,000 persons-week)

as compared with that of other Spanish regions during the first wave of COVID19 pandemic. In this epidemic context (low incidence), our data supports that increasing age, nursing-home residence, pre-existing cancer, neurological, renal and cardiac disease are independent major predisposing conditions to suffer COVID19 among middle-aged and older adults. Patients receiving diuretics, antiplatelet drugs and benzodiazepines were also at increased risk.

Oppositely, patients taking statins, renin-angiotensin-aldosterone system inhibitors and those community-dwelling individuals that received influenza vaccination in prior autumn presented decreased risk. NOTE: HRs denotes Hazard ratios, and were calculated for those who had the condition as compared with those who had not the condition. In multivariable-adjusted analysis the HRs were adjusted for age (continuous years), sex, residence, comorbidities/underlying conditions and chronic medications use. CIs denote confidence intervals.

Listings of WHO's response to COVID-19

Weekly epidemiological update-27

Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 300

Association between COVID-19 prognosis and disease presentation, comorbidities and chronic treatment of hospitalized patients

Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region

Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Association of cardiovascular disease and 10 other pre-existing comorbidities with COVID-19 mortality: A systematic review and meta-analysis

Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study

Defining the epidemiology of Covid-19-studies needed

Evaluación de la incidencia y perfil de riesgo de Covid-19 según comorbilidad previa en adultos ≥50 años del área de Tarragona

Influence of prior comorbidities and chronic medications use on the risk of COVID-19 in adults: a population-based cohort study in Tarragona

Statistical institute of Catalonia

WMA Declaration of Helsinki -Ethical Principles for Medical Research Involving Human Subjects

Rationale and design of the CAPAMIS study: effectiveness of pneumococcal vaccination against community-acquired pneumonia, acute myocardial infarction and stroke

Procediment d'actuació enfront de casos d'infecció pel nou coronavirus SARSCoV-2

Who Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2020

Applied Survival Analysis. Regression Modelling of Time to Event Data

What do we know about SARS-CoV-2 transmission? A systematic review and meta-analysis of the secondary attack rate and associated risk factors

Calidad e innovación. Centro de Coordinación de Alertas y Emergencias Sanitarias. Actualización nº 152. Enfermedad por el coronavirus (COVID-19). 30.06.2020

European Centers for Disease Prevention and Control. Situation updates on COVID19

Estudio ENE-COVID19: informe final. Estudio nacional de seroepidemiología de la infección por SARS-CoV-2 en España

COVID-19, equipoise and observational studies: a reminder of forgotten issues

Markers Associated with COVID-19 Susceptibility, Resistance, and Severity

People with Certain Medical Conditions

The impact of COPD and smoking history on the severity of COVID-19: A systemic review and meta-analysis

Active smoking is not associated with severity of coronavirus disease 2019 (COVID-19)

Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19

Meta-analysis of Effect of Statins in Patients with COVID-19

The possible beneficial adjuvant effect of influenza vaccine to minimize the severity of COVID-19

Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis)

NOTE: P-values in univariate analysis were calculated by chi-squared, or Fisher's test as appropriate, comparing percentages in the study population vs COVID-19 cases; IR denotes incidence rates per 100.000 persons-week; CIs denotes confidence intervals for incidence rates and were calculated assuming a Poisson distribution for uncommon events